Tirelizumab is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. Lead sponsors include Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) and Sichuan Cancer Hospital and Research Institute (1). Registered phase: Phase 2. Conditions studied include Head and Neck Squamous Cell Carcinoma; Oral Cancer; Esophageal Squamous Cell Carcinoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05941338 | Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC (ClinicalTrials.gov ↗) Head and Neck Squamous Cell Carcinoma, Oral Cancer |
Phase 2 | Recruiting |
| NCT05189730 | Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC (ClinicalTrials.gov ↗) Esophageal Squamous Cell Carcinoma |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Head and Neck Squamous Cell Carcinoma | 1 |
| Oral Cancer | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Sichuan Cancer Hospital and Research Institute | 1 |
| Register | Tirelizumab trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tirelizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tirelizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.